CClinicalTrials.gg
RecruitingNCT07814157Updated Sep 10, 2026

PCI Registry Basel

An observational study in Coronary Artery Disease, Coronary Stenosis and Coronary Occlusion, sponsored by University Hospital, Basel, Switzerland. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by University Hospital, Basel, Switzerland · Observational

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
10,000
Ages
18 Years and older
Sex
All
01

Study summary

This registry aims to learn more about the best ways to treat coronary artery disease. Information from routine medical care will be collected to compare different treatment approaches, including drug-eluting stents, drug-coated balloons (DCB), and bioresorbable scaffolds (BRS), which gradually dissolve over time. The registry will include people with coronary artery disease who receive an intervention (percutaneous coronary intervention), including those undergoing more complex procedures. By studying treatment outcomes over time, the Registry aims to better understand which therapies work best for different groups of patients and to improve future care for people with coronary artery disease.

Read the detailed description

The PCI Registry Basel is established to systematically collect real-world data on all patients (≥18 years) undergoing percutaneous coronary interventions (PCI) at the University Hospital Basel. The primary purpose of the registry is to investigate the best treatment strategies in patients with coronary artery disease (CAD) and their associated outcomes in routine clinical practice, including complex procedures (e.g. chronic total occlusions (CTO), bifurcation lesions, left main interventions), the use of drug-coated balloons (DCB) and bioresorbable scaffolds (BRS), as well as standard drug-eluting stent (DES) implantation.

Data are derived retrospectively from routine clinical practice at the University Hospital Basel. Relevant procedural, clinical, and follow-up information is extracted from existing sources such as the catheterization lab reports, and the electronic health record (Cardioapp). No additional data collection or invasive study-specific interventions are performed for the purpose of this registry.

Where applicable, data from previous research projects or registries may also be incorporated, provided that all legal and ethical requirements are satisfied. All data will be pseudonymised before analysis. A secure decoding key linking registry numbers to patient identifiers is kept separately and is accessible only to authorized personnel under the responsibility of the Principal Investigator.

02

Conditions studied

  • Coronary Artery Disease
  • Coronary Stenosis
  • Coronary Occlusion

Keywords

  • Registry
  • Percutaneous coronary interventions
  • Coronary artery disease
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consits of patients undergoing percutaneous coronary interventions (PCI) at the University Hospital Basel

Inclusion criteria

Patients treated at the University Hospital Basel

  • Undergoing complex PCI (e.g. left main, bifurcation, multivessel PCI, rotational atherectomy or other calcium modification, complex anatomy). The definition complex will be a clinical/ procedural/ anatomical definition made by the operator.
  • Undergoing CTO or CHIP (Complex High-risk Indicated Patient) procedures
  • Treated with a DCB strategy
  • Treated with a BRS

Exclusion criteria

Exclusion Criteria:

  • Patients under 18 years of age
04

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
10,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
05

What researchers measure

Primary outcomes

  1. Target Vessel Failure (TVF)

    Composite endpoint defined as the occurrence of cardiovascular death, target vessel myocardial infarction, or unplanned target vessel revascularisation.

    Time frame: Through study completion, an average of 1 year

Other outcomes

  1. All-Cause Mortality

    Death from any cause as documented in the available medical records.

    Time frame: Through study completion, an average of 1 year

  2. Cardiovascular Mortality

    Death attributed to a cardiovascular cause as documented in the medical records.

    Time frame: Through study completion, an average of 1 year

  3. Occurrence of Myocardial Infarction

    Documented occurrence of myocardial infarction in the medical records.

    Time frame: Through study completion, an average of 1 year

  4. Procedural Success Rate

    Proportion of PCI procedures meeting the predefined criteria for procedural success.

    Time frame: Through study completion, an average of 1 year

  5. Procedural Complication Rate

    Proportion of PCI procedures with documented procedural complications

    Time frame: Through study completion, an average of 1 year

  6. Rate of Rescue Stenting

    Proportion of PCI procedures requiring unplanned rescue stent implantation.

    Time frame: Through study completion, an average of 1 year

  7. Unplanned hospitalisation for angina

    Unplanned hospitalisation due to angina as documented in the medical records

    Time frame: Through study completion, an average of 1 year

  8. Unplanned hospitalisation for heart failure

    Unplanned hospitalisation due to heart failure, as documented in the medical records.

    Time frame: Through study completion, an average of 1 year

06

Study locations

1 of 1 sites recruiting
  • University Hospital Basel
    Basel, Canton of Basel-City 4031, Switzerland
    • Gregor Leibundgut, Prof. Dr. med. · Contact · gregor.leibundgut@usb.ch · (0)61 556 58 18
    • Jasper Boeddinghaus, PD Dr. med. · Contact · jasper.boeddinghaus@usb.ch · (0)61 328 78 97
    • Gregor Leibundgut, Prof. Dr. med. · Principal investigator
    • Jasper Boeddinghaus, PD Dr. med. · Principal investigator
    Recruiting
07

Registry details

Key details

Study ID
NCT07814157
Lead sponsor
University Hospital, Basel, Switzerland
Responsible party
Sponsor
First posted
Sep 10, 2026
Start date
Oct 1, 2025
Primary completion
Oct 2035 (estimated)
Completion
Oct 2035 (estimated)
Last update
Sep 10, 2026

Study contacts

Gregor Leibundgut, Prof. Dr. med.
Contact
gregor.leibundgut@usb.ch
(0)61 556 58 18 ext. 0041
Jasper Boeddinghaus, PD Dr. med.
Contact
jasper.boeddinghaus@usb.ch
(0)61 328 78 97 ext. 0041
Gregor Leibundgut, Prof. Dr. med.
principal investigator · University Hospital, Basel, Switzerland
Jasper Boeddinghaus, PD Dr. med.
principal investigator · University Hospital, Basel, Switzerland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion